Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data

Expert Rev Clin Immunol. 2020 Jun;16(6):599-620. doi: 10.1080/1744666X.2020.1776116. Epub 2020 Jun 22.


Introduction: Psoriasis is a very common chronic inflammatory skin disease affecting up to 3% of the general population with 75% of the psoriasis subjects being affected by a mild form of disease. Hence, topical therapy is the most frequent employed treatment in psoriasis also because it can be easily combined with systemic therapy. In this context, calcipotriol/betamethasone dipropionate (Cal/BD) fixed-dose association represents the first-line treatment due to its efficacy and once-daily application. Different Cal/BD formulations, such as ointment, gel (topical suspension), and aerosol foam, are approved by US Food and Drug Administration.

Areas covered: For this review, relevant English literature (trials, real-life studies, case series, and reviews) regarding Cal/BD different formulations efficacy in psoriasis was searched for through to 28 January 2020. The following database were consulted: PubMed, Embase, the Cochrane Library, Google Scholar, EBSCO, and

Expert opinion: Cal/BD formulations are efficacious treatment for psoriasis. Cal/BD aerosol foam shows a higher efficacy compared to Cal/BD ointment or gel formulations, appearing as a game-changer in psoriasis therapy not only for mild disease but also for moderate psoriasis as well as in selected severe cases in combination with systemic treatments.

Keywords: Aerosol foam; calcipotriol/betamethasone dipropionate; efficacy; gel; ointment; psoriasis; treatment.

Publication types

  • Review
  • Video-Audio Media

MeSH terms

  • Administration, Cutaneous
  • Betamethasone / analogs & derivatives*
  • Betamethasone / therapeutic use
  • Calcitriol / analogs & derivatives*
  • Calcitriol / therapeutic use
  • Dermatologic Agents / therapeutic use*
  • Drug Combinations
  • Humans
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Psoriasis / pathology


  • Dermatologic Agents
  • Drug Combinations
  • calcipotriene
  • betamethasone-17,21-dipropionate
  • Betamethasone
  • Calcitriol